Precision Optics (POCI)
Market Price (3/30/2026): $4.25 | Market Cap: $32.8 MilSector: Health Care | Industry: Health Care Equipment
Precision Optics (POCI)
Market Price (3/30/2026): $4.25Market Cap: $32.8 MilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 31% | Weak multi-year price returns2Y Excs Rtn is -51%, 3Y Excs Rtn is -93% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -6.7 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -28% |
| Low stock price volatilityVol 12M is 49% | Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -11%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -13% | |
| Megatrend and thematic driversMegatrends include Autonomous Technologies, Biotechnology & Genomics, and Advanced Aviation & Space. Themes include Machine Vision, Show more. | Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -25% | |
| Key risksPOCI key risks include [1] ongoing financial losses and potential funding needs, Show more. |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 31% |
| Low stock price volatilityVol 12M is 49% |
| Megatrend and thematic driversMegatrends include Autonomous Technologies, Biotechnology & Genomics, and Advanced Aviation & Space. Themes include Machine Vision, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -51%, 3Y Excs Rtn is -93% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -6.7 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -28% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -11%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -13% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -25% |
| Key risksPOCI key risks include [1] ongoing financial losses and potential funding needs, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Precision Optics (POCI) stock has lost about 10% since 11/30/2025 because of the following key factors:
1. Significant Decline in Gross Margins. Precision Optics reported a substantial drop in its gross margins during the specified period. For the first quarter of fiscal year 2026 (ended September 30, 2025), reported on November 13, 2025, gross margins decreased to 14.2% from 26.6% in the same quarter of the previous fiscal year. This trend worsened in the second quarter of fiscal year 2026 (ended December 31, 2025), reported on February 17, 2026, with gross margins plummeting further to 2.8% compared to 23.6% in the prior year period. This sharp contraction indicates significant pressure on the company's profitability.
2. Widening Net Losses and Negative Adjusted EBITDA. The company experienced escalating net losses and continued negative Adjusted EBITDA. In Q1 FY2026, the net loss widened to $(1.6) million from $(1.3) million in the prior year, with Adjusted EBITDA at $(1.2) million compared to $(1.0) million. This negative trend accelerated in Q2 FY2026, where the net loss further expanded to $1.78 million (compared to $1.0 million in the prior year) and Adjusted EBITDA remained negative at $(1.5) million (compared to $(0.6) million in the prior year period).
Show more
1. Significant Decline in Gross Margins. Precision Optics reported a substantial drop in its gross margins during the specified period. For the first quarter of fiscal year 2026 (ended September 30, 2025), reported on November 13, 2025, gross margins decreased to 14.2% from 26.6% in the same quarter of the previous fiscal year. This trend worsened in the second quarter of fiscal year 2026 (ended December 31, 2025), reported on February 17, 2026, with gross margins plummeting further to 2.8% compared to 23.6% in the prior year period. This sharp contraction indicates significant pressure on the company's profitability.
2. Widening Net Losses and Negative Adjusted EBITDA. The company experienced escalating net losses and continued negative Adjusted EBITDA. In Q1 FY2026, the net loss widened to $(1.6) million from $(1.3) million in the prior year, with Adjusted EBITDA at $(1.2) million compared to $(1.0) million. This negative trend accelerated in Q2 FY2026, where the net loss further expanded to $1.78 million (compared to $1.0 million in the prior year) and Adjusted EBITDA remained negative at $(1.5) million (compared to $(0.6) million in the prior year period).
Show more
Stock Movement Drivers
Fundamental Drivers
The -10.7% change in POCI stock from 11/30/2025 to 3/29/2026 was primarily driven by a -21.1% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.69 | 4.19 | -10.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 22 | 24 | 13.2% |
| P/S Multiple | 1.7 | 1.3 | -21.1% |
| Shares Outstanding (Mil) | 8 | 8 | 0.0% |
| Cumulative Contribution | -10.7% |
Market Drivers
11/30/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| POCI | -10.7% | |
| Market (SPY) | -5.3% | -7.8% |
| Sector (XLV) | -8.7% | 9.9% |
Fundamental Drivers
The -10.9% change in POCI stock from 8/31/2025 to 3/29/2026 was primarily driven by a -28.2% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.70 | 4.19 | -10.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 18 | 24 | 38.5% |
| P/S Multiple | 1.8 | 1.3 | -28.2% |
| Shares Outstanding (Mil) | 7 | 8 | -10.3% |
| Cumulative Contribution | -10.9% |
Market Drivers
8/31/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| POCI | -10.9% | |
| Market (SPY) | 0.6% | 0.5% |
| Sector (XLV) | 5.2% | 19.1% |
Fundamental Drivers
The -8.5% change in POCI stock from 2/28/2025 to 3/29/2026 was primarily driven by a -17.7% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.58 | 4.19 | -8.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 19 | 24 | 30.7% |
| P/S Multiple | 1.6 | 1.3 | -15.0% |
| Shares Outstanding (Mil) | 6 | 8 | -17.7% |
| Cumulative Contribution | -8.5% |
Market Drivers
2/28/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| POCI | -8.5% | |
| Market (SPY) | 9.8% | 4.6% |
| Sector (XLV) | -2.1% | 14.2% |
Fundamental Drivers
The -40.6% change in POCI stock from 2/28/2023 to 3/29/2026 was primarily driven by a -32.0% change in the company's P/S Multiple.| (LTM values as of) | 2282023 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.05 | 4.19 | -40.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 20 | 24 | 19.6% |
| P/S Multiple | 1.9 | 1.3 | -32.0% |
| Shares Outstanding (Mil) | 6 | 8 | -26.9% |
| Cumulative Contribution | -40.6% |
Market Drivers
2/28/2023 to 3/29/2026| Return | Correlation | |
|---|---|---|
| POCI | -40.6% | |
| Market (SPY) | 69.4% | 9.6% |
| Sector (XLV) | 18.4% | 8.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| POCI Return | 0% | 13813% | 8% | -20% | -13% | 1% | 10425% |
| Peers Return | 4% | -18% | 8% | 52% | 88% | 26% | 234% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| POCI Win Rate | 0% | 8% | 58% | 58% | 42% | 33% | |
| Peers Win Rate | 52% | 43% | 53% | 63% | 53% | 60% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| POCI Max Drawdown | 0% | 0% | -2% | -37% | -19% | -2% | |
| Peers Max Drawdown | -23% | -36% | -23% | -11% | -31% | -10% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: AMS, IIIV, COHR, LITE, MTSI.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
| Event | POCI | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -24.3% | -25.4% |
| % Gain to Breakeven | 32.1% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2008 Global Financial Crisis | ||
| % Loss | -92.3% | -56.8% |
| % Gain to Breakeven | 1200.0% | 131.3% |
| Time to Breakeven | 5,112 days | 1,480 days |
Compare to AMS, IIIV, COHR, LITE, MTSI
In The Past
Precision Optics's stock fell -24.3% during the 2022 Inflation Shock from a high on 3/3/2023. A -24.3% loss requires a 32.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Precision Optics (POCI)
Precision Optics Corporation, Inc. designs, develops, manufactures, and sells specialized optical and illumination systems and related components primarily in the United States and the European Economic Area. The company offers medical instrumentation products, including endoscopes and endocouplers, as well as other custom imaging and illumination products, such as Microprecision lenses and micro medical cameras, and 3D endoscopes for use in minimally invasive surgical procedures by hospitals and physicians. It also provides components and assemblies, which are designed for industrial and military use. The company markets its products to original equipment manufacturers through medical device companies. Precision Optics Corporation, Inc. was incorporated in 1982 and is based in Gardner, Massachusetts.
AI Analysis | Feedback
Analogies for Precision Optics (POCI):
- Think of them as a "Carl Zeiss for specialized miniature medical imaging and endoscopy components."
- They are like the "Intel Inside" for advanced optical systems used in medical devices and industrial equipment.
AI Analysis | Feedback
- Medical Instrumentation Products: Includes specialized optical and illumination systems such as endoscopes, endocouplers, micro medical cameras, and 3D endoscopes for minimally invasive surgical procedures.
- Industrial and Military Components: Custom-designed optical and illumination components and assemblies for industrial and military applications.
AI Analysis | Feedback
Major Customers of Precision Optics (POCI)
Based on the provided information, Precision Optics (POCI) primarily sells its products to other companies rather than individuals. While specific customer company names are not disclosed in the background description, the company's major customers can be identified by the types of companies it serves:
- Original Equipment Manufacturers (OEMs)
- Medical Device Companies (who then market products to hospitals and physicians for use in minimally invasive surgical procedures)
- Companies serving the industrial and military sectors (for components and assemblies)
AI Analysis | Feedback
nullAI Analysis | Feedback
Joseph Forkey, Chief Executive Officer, President, and TreasurerDr. Joseph Forkey joined Precision Optics in 2003 and has served as Chief Executive Officer, President, and Treasurer since February 8, 2011. He has over 30 years of experience in inter-disciplinary optical technology across the medical device and defense/aerospace markets, both in academic and industrial settings. Prior to his CEO role, he held positions of Executive Vice President and Chief Scientific Officer from April 2006 to February 2011, and Chief Scientist from September 2003 to April 2006. Dr. Forkey was also a member of the Board of Directors since 2006 and served as its Chairman from February 2011 to July 2014. He holds an M.A. and Ph.D. in Applied Physics/Mechanical and Aerospace Engineering from Princeton University and B.A.s in Physics and Mathematics from Cornell University.
Wayne Coll, Chief Financial Officer
Wayne Coll was appointed Chief Financial Officer effective June 12, 2023, bringing over 30 years of senior financial executive experience, primarily within medical device-based businesses. He is an experienced public company CFO with expertise in driving business models, executing strategic M&A activities, and managing access to capital markets. Before joining Precision Optics, Mr. Coll served as CFO at Flowonix Medical Incorporated (July 2021-June 2023), Micron Products, Inc. (a publicly traded medical devices and contract manufacturer, July 2019–July 2021), Keystone Dental, Inc. (October 2018-May 2019), Modern Dental Laboratory USA (October 2013-September 2018), and Pluromed (a medical device company acquired by Genzyme/Sanofi, November 2011-September 2013). He also spent nearly 20 years at National Dentex Corporation, a publicly traded dental laboratory, including 4-5 years as CFO.
Joseph Traut, Chief Operating Officer
Joseph Traut was appointed Chief Operating Officer effective October 1, 2025. He brings more than 20 years of experience leading manufacturing, operations, and technology transfer initiatives within the medical device and diagnostics industries. Most recently, Mr. Traut served as Vice President of Operations at T2 Biosystems and previously as Vice President of Technology Transfer at LumiraDx. From 2017 to 2021, he was Vice President of Manufacturing Solutions at Ximedica (now part of Veranex), where he partnered with medical technology companies for product industrialization, supply chain strengthening, and preparing organizations for commercialization and growth. Mr. Traut holds an MBA in Management of Technology from Bentley University.
Jeff DiRubio, EVP, Sales & Marketing
Jeff DiRubio serves as the Executive Vice President of Sales & Marketing.
Jonathan Everett, VP of Engineering
Jonathan Everett holds the position of Vice President of Engineering.
AI Analysis | Feedback
The key risks to Precision Optics (POCI) primarily revolve around its financial stability, supply chain vulnerabilities, and customer concentration.
- Financial Instability and Going Concern Uncertainty: Precision Optics faces significant financial challenges, with current cash reserves insufficient to fund planned operations for at least one year, explicitly raising substantial doubt about its ability to continue as a going concern. The company has experienced severe margin compression and widening net losses despite revenue growth, primarily due to manufacturing yield issues, startup problems, and under-absorbed overhead. Furthermore, it has required waivers for minimum annual debt service coverage ratios and has failed to meet compliance for future advances, posing a substantial financing risk.
- Supply Chain Vulnerabilities: The company is highly reliant on a limited number of suppliers for critical raw materials, such as precision-grade optical glass and CMOS image sensors, with some suppliers located in China. This dependence exposes Precision Optics to potential disruptions, increased costs, and weakened competitive positioning from U.S. tariff policy changes, trade restrictions, or other supply chain interruptions.
- Customer Concentration: Precision Optics relies heavily on a small number of key customers. The loss of any significant customer could lead to a substantial decline in revenues and materially impact the company's financial performance.
AI Analysis | Feedback
nullAI Analysis | Feedback
Precision Optics Corporation, Inc. (POCI) designs, develops, manufactures, and sells specialized optical and illumination systems, with a significant focus on medical instrumentation. The addressable markets for their main products and services, primarily in the medical sector, are substantial:
Medical Cameras (including micro medical cameras and 3D endoscopes)
- The global medical camera market was valued at approximately USD 3.54 billion in 2024 and is projected to grow to USD 6.73 billion by 2033, exhibiting a Compound Annual Growth Rate (CAGR) of 7.4% during the forecast period (2026–2033). Other estimates place the global market at USD 2.7 billion in 2022, with a projection to reach USD 5.9 billion by 2032 at over 7% CAGR. Another report estimates the global market at USD 4.44 billion in 2025, projected to grow to USD 7.57 billion by 2034, with a CAGR of 6.2%.
- In North America, the medical camera market was valued at over USD 860 million in 2022.
- The European medical camera market was valued at USD 0.97 billion in 2024 and is forecasted to grow to USD 2.10 billion by 2033, at a CAGR of 8.9%.
- The endoscopy cameras segment alone accounted for the largest share of the medical camera market in 2023 and 2025, holding over 46% of the market share in 2023. High-definition (HD) cameras, which include those used in endoscopy, represented over 62% of the medical camera market's resolution segment in 2023.
Endoscopes (including endoscopes and components like Microprecision lenses and endocouplers)
- The global endoscopes market size was estimated at USD 25.18 billion in 2024 and is expected to reach USD 37.01 billion by 2032, growing at a CAGR of 4.93% from 2025-2032. Other projections indicate a global market size of USD 26.63 billion in 2025, expanding to USD 41.17 billion by 2034, at a CAGR of 4.96%.
- The U.S. endoscopes market was valued at USD 4.78 billion in 2024 and is projected to reach USD 11.22 billion by 2034, growing at a CAGR of 9% from 2025 to 2034.
- The Europe endoscopes market generated a revenue of USD 3,687.2 million in 2023 and is expected to grow at a CAGR of 9% from 2024 to 2030, reaching a projected revenue of USD 6,730.3 million by 2030.
- Within the broader endoscopy devices market, the U.S. endoscopy devices market size was estimated at USD 21.07 billion in 2023 and is projected to grow at a CAGR of 6.4% from 2024 to 2030. Similarly, the U.S. endoscopy devices market size accounted for USD 17,130 million in 2024 and is expected to exceed USD 35,970 million by 2034, growing at a CAGR of 7.7% from 2025 to 2034.
- The Europe endoscopy devices market was valued at USD 9.42 billion in 2024, is estimated to reach USD 10.05 billion in 2025, and is projected to grow at a CAGR of 6.65% from 2025 to 2033, reaching USD 16.82 billion by 2033.
- The Europe disposable endoscopes market, a sub-segment, was estimated at USD 777.2 million in 2024 and is expected to reach USD 1.21 billion by 2030, registering a CAGR of 7.73% from 2025 to 2030.
Minimally Invasive Surgical Devices
Precision Optics' products contribute to the larger minimally invasive surgical (MIS) devices market due to their use in minimally invasive surgical procedures.
- The global minimally invasive surgical instruments market size was estimated at USD 31.65 billion in 2023 and is projected to reach USD 63.04 billion by 2030, growing at a CAGR of 10.3% from 2024 to 2030. Another estimate places the global market at USD 30,798.01 million in 2025, projected to grow to USD 53,259.85 million by 2034, registering a CAGR of 7.13% from 2026 to 2034.
- North America held the dominant share in the global minimally invasive surgical instruments market in 2023. The U.S. minimally invasive surgery devices market was valued at USD 8.42 billion in 2024 and is expected to reach USD 12.14 billion by 2033, exhibiting a CAGR of 3.73%.
- The minimally invasive surgical instruments market in Europe is expected to reach a projected revenue of USD 17,009.6 million by 2030, with a CAGR of 10.5% from 2024 to 2030. The Europe minimally invasive surgery devices market recorded a value of USD 13.14 billion in 2025 and is projected to total USD 23.95 billion by 2033, registering an estimated CAGR of 7.8%.
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for Precision Optics (POCI)
Precision Optics (POCI) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market trends, primarily focusing on transitioning its robust engineering pipeline into full-scale production and expanding its presence in critical sectors.
- Transition of New Programs from Engineering to Production: A significant driver of future revenue growth for Precision Optics is the successful transition of new programs from the engineering and development phase to full production. This strategic shift is expected to substantially increase manufacturing revenue, with systems manufacturing projected to grow by at least 75% in fiscal year 2026. The company anticipates achieving record quarterly revenue run rates by the end of the fiscal year as these programs move into production.
- Expansion in the Medical Device Market with Single-Use Cystoscope Program: The single-use cystoscope program is a key growth area within the medical device market. Precision Optics anticipates continued increases in revenue from this program throughout fiscal 2026, supported by growing demand from customers and end-users, as well as the introduction of a partial second production line. Management is actively capitalizing on growth opportunities within the medical sector.
- Growth in the Defense Aerospace Market: Precision Optics is strategically expanding its footprint in the defense aerospace market. A new defense aerospace program has already begun contributing to production revenue, and the company has added sales representatives with experience in this sector. New development programs in the aerospace domain are also underway, and the aerospace program alone had a backlog exceeding $9 million as of the first quarter of fiscal year 2026.
- Recovery and Growth in the Engineering Pipeline and Product Development: The company's strong engineering pipeline is a crucial indicator of future production revenue potential. Precision Optics expects a significant recovery in its product development pipeline and has secured new large development agreements. These agreements, totaling approximately $1.4 million, are focused on advanced applications such as augmented reality systems for defense and high-resolution borescopes for jet engine inspection, indicating a healthy pipeline for future projects.
- Introduction and Adoption of the Unity Platform: The Unity platform, designed for modular endoscope development, represents a new product launch that is expanding the company's pipeline opportunities. Management has highlighted the substantial benefits of the Unity Imaging Platform to customers and expressed confidence that it will contribute to future growth. Precision Optics has also increased its research and development spending due to investments in the Unity platform.
AI Analysis | Feedback
Capital Allocation Decisions (Last 3-5 Years)
Share Issuance
- The number of shares outstanding for Precision Optics increased by 21.52% in the year leading up to March 3, 2026, reaching 7.72 million shares.
- Based on an average share price of approximately $4.50, this represents an estimated issuance of around $6.17 million in new shares during that period.
- Shares outstanding also saw an increase from 6 million as of September 30, 2024, to 8 million as of September 30, 2025.
Capital Expenditures
- Precision Optics reported annual capital expenditures of $233.5K in 2025.
- Annual capital expenditures for 2024 were $293.9K, and $50K in 2023.
- The trailing twelve months (TTM) capital expenditures as of December 31, 2025, totaled approximately $574.5K.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Precision Optics Earnings Notes | 12/16/2025 | |
| How Low Can Precision Optics Stock Really Go? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to POCI.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 123.83 |
| Mkt Cap | 8.7 |
| Rev LTM | 622 |
| Op Inc LTM | 6 |
| FCF LTM | -7 |
| FCF 3Y Avg | 7 |
| CFO LTM | 110 |
| CFO 3Y Avg | 81 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 23.9% |
| Rev Chg 3Y Avg | 10.6% |
| Rev Chg Q | 21.0% |
| QoQ Delta Rev Chg LTM | 4.8% |
| Op Mgn LTM | 1.4% |
| Op Mgn 3Y Avg | 4.5% |
| QoQ Delta Op Mgn LTM | 1.1% |
| CFO/Rev LTM | 9.0% |
| CFO/Rev 3Y Avg | 11.9% |
| FCF/Rev LTM | -1.5% |
| FCF/Rev 3Y Avg | -0.8% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 8.7 |
| P/S | 4.4 |
| P/EBIT | 62.4 |
| P/E | 68.2 |
| P/CFO | 71.4 |
| Total Yield | 0.6% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 0.1% |
| D/E | 0.1 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -4.0% |
| 3M Rtn | 13.3% |
| 6M Rtn | 34.8% |
| 12M Rtn | 65.2% |
| 3Y Rtn | 107.7% |
| 1M Excs Rtn | 5.3% |
| 3M Excs Rtn | 22.8% |
| 6M Excs Rtn | 42.2% |
| 12M Excs Rtn | 42.8% |
| 3Y Excs Rtn | 47.5% |
Price Behavior
Price Behavior
| Market Price | $4.19 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 12/29/2006 | |
| Distance from 52W High | -29.5% | |
| 50 Days | 200 Days | |
| DMA Price | $4.66 | $4.60 |
| DMA Trend | indeterminate | up |
| Distance from DMA | -10.0% | -8.9% |
| 3M | 1YR | |
| Volatility | 55.5% | 49.3% |
| Downside Capture | -0.02 | 0.36 |
| Upside Capture | -6.38 | 43.77 |
| Correlation (SPY) | -5.3% | 7.7% |
POCI Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -1.64 | -0.29 | -0.34 | 0.11 | 0.16 | 0.32 |
| Up Beta | -0.82 | 0.79 | 1.47 | 0.32 | 0.07 | 0.56 |
| Down Beta | -2.24 | -1.27 | -0.60 | -0.31 | -0.05 | 0.01 |
| Up Capture | -264% | -9% | -87% | 7% | 24% | 4% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 6 | 18 | 25 | 48 | 105 | 311 |
| Down Capture | -31% | -21% | -49% | 44% | 54% | 70% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 15 | 21 | 34 | 70 | 133 | 364 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with POCI | |
|---|---|---|---|---|
| POCI | 1.8% | 49.5% | 0.19 | - |
| Sector ETF (XLV) | 0.3% | 17.6% | -0.13 | 17.1% |
| Equity (SPY) | 14.5% | 18.9% | 0.59 | 7.9% |
| Gold (GLD) | 50.2% | 27.7% | 1.46 | -2.7% |
| Commodities (DBC) | 17.8% | 17.6% | 0.85 | -6.8% |
| Real Estate (VNQ) | 0.4% | 16.4% | -0.15 | 8.2% |
| Bitcoin (BTCUSD) | -23.7% | 44.2% | -0.49 | 1.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with POCI | |
|---|---|---|---|---|
| POCI | -0.2% | 50.0% | 0.16 | - |
| Sector ETF (XLV) | 6.0% | 14.5% | 0.23 | 9.5% |
| Equity (SPY) | 11.8% | 17.0% | 0.54 | 9.7% |
| Gold (GLD) | 20.7% | 17.7% | 0.96 | -0.8% |
| Commodities (DBC) | 11.6% | 18.9% | 0.50 | -3.5% |
| Real Estate (VNQ) | 3.0% | 18.8% | 0.07 | 6.2% |
| Bitcoin (BTCUSD) | 4.0% | 56.6% | 0.29 | 5.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with POCI | |
|---|---|---|---|---|
| POCI | -0.1% | 50.0% | 0.16 | - |
| Sector ETF (XLV) | 9.7% | 16.5% | 0.48 | 9.5% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 9.7% |
| Gold (GLD) | 13.3% | 15.8% | 0.70 | -0.8% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | -3.5% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 6.2% |
| Bitcoin (BTCUSD) | 66.4% | 66.8% | 1.06 | 5.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/14/2024 | -9.2% | -11.8% | -10.1% |
| 10/20/2022 | 0.0% | 0.0% | 14,475.0% |
| SUMMARY STATS | |||
| # Positive | 1 | 1 | 1 |
| # Negative | 1 | 1 | 1 |
| Median Positive | 0.0% | 0.0% | 14,475.0% |
| Median Negative | -9.2% | -11.8% | -10.1% |
| Max Positive | 0.0% | 0.0% | 14,475.0% |
| Max Negative | -9.2% | -11.8% | -10.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/17/2026 | 10-Q |
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 09/29/2025 | 10-K |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 02/13/2025 | 10-Q |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 09/30/2024 | 10-K |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 02/14/2024 | 10-Q |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 09/28/2023 | 10-K |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 02/14/2023 | 10-Q |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 09/27/2022 | 10-K |
| 03/31/2022 | 05/16/2022 | 10-Q |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.